FDA said to misuse "approvable" letters to delay decisions

06/7/2006 | Bloomberg Businessweek

Drugmakers complain the FDA is issuing "approvable" letters to gain more time to review submitted drugs, allowing the agency to avoid the six- to 10-month time limit for it to act. Some say the increase in the number of approvable letters is indicative of an overall slowdown at the agency.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI